Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015 Feb 2;10(2):e0113999.
doi: 10.1371/journal.pone.0113999. eCollection 2015.

Upper limb strength and function changes during a one-year follow-up in non-ambulant patients with Duchenne Muscular Dystrophy: an observational multicenter trial

Andreea Mihaela Seferian  1 , Amélie Moraux  1 , Mélanie Annoussamy  1 , Aurélie Canal  1 , Valérie Decostre  1 , Oumar Diebate  1 , Anne-Gaëlle Le Moing  2 , Teresa Gidaro  1 , Nicolas Deconinck  3 , Frauke Van Parys  3 , Wendy Vereecke  3 , Sylvia Wittevrongel  3 , Michèle Mayer  4 , Kim Maincent  4 , Isabelle Desguerre  5 , Christine Thémar-Noël  1 , Jean-Marie Cuisset  6 , Vincent Tiffreau  7 , Severine Denis  8 , Virginie Jousten  8 , Susana Quijano-Roy  9 , Thomas Voit  10 , Jean-Yves Hogrel  1 , Laurent Servais  11
Affiliations
Clinical Trial

Upper limb strength and function changes during a one-year follow-up in non-ambulant patients with Duchenne Muscular Dystrophy: an observational multicenter trial

Andreea Mihaela Seferian et al. PLoS One. .

Abstract

Introduction: Upper limb evaluation of patients with Duchenne Muscular Dystrophy is crucially important to evaluations of efficacy of new treatments in non-ambulant patients. In patients who have lost ambulation, there are few validated and informative outcome measures. In addition, longitudinal data demonstrating sensitivity to clinical evolution of outcome measures over short-term periods are lacking.

Patients and methods: We report here the results of a one-year multicenter study using specifically designed tools to assess grip, pinch strength, and hand function in wheelchair-bound patients. Our study assessed 53 non-ambulant patients with Duchenne muscular dystrophy aged 17.1 ± 4.8 years (range: 9 - 28.1 years). The average Brooke functional score of these patients was 4.6 ± 1.1. The average forced vital capacity was 44.5% predicted and 19 patients used non-invasive ventilation. Patients were assessed at baseline, 6 months, and one year using the Motor Function Measure and innovative devices (namely the MyoSet composed of MyoGrip, MyoPinch, and MoviPlate).

Results: Our study confirmed preliminary data previously reported regarding feasibility of use and of reliability of the MyoSet and the correlation at baseline between distal strength and clinical outcomes such as FVC, Brooke score, age, and duration since loss of ambulation. A significant correlation was observed between the distal upper limb strength and clinical variables. The sensitive dynamometers (MyoGrip and MyoPinch) and MoviPlate captured a 12-month change in non-ambulant Duchenne muscular dystrophy patients of all ages.

Trial registration: ClinicalTrials.gov NCT00993161 NCT00993161.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: JYH is the inventor of the MyoGrip. JYH and AM are co-inventors of the MyoPinch. JYH, AC, LS and TV are co-inventors of the MoviPlate. This does not alter the authors’ adherence to all PLOS ONE policies on sharing data and materials.

Figures

Figure 1
Figure 1. Flow chart of patients included in the clinical protocol.
Figure 2
Figure 2. Correlation between MyoSet values at baseline and clinical data.
Figure 3
Figure 3. Relation between MyoSet values at baseline, at 6 months, and at one year with duration since loss of ambulation.
Figure 4
Figure 4. Relation between MFM-D2 and MFM-D3 sub-scores and total score and duration since loss of ambulation at baseline at 6 months and at one year.
See this image and copyright information in PMC

References

    1. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, et al. (2010) Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 9: 177–189. 10.1016/S1474-4422(09)70272-8 - DOI - PubMed
    1. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, et al. (2010) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 9: 77–93. 10.1016/S1474-4422(09)70272-8 - DOI - PubMed
    1. Cirak S, Arechavala-Gomeza V, Guglieri M, Feng L, Torelli S, et al. (2011) Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378: 595–605. 10.1016/S0140-6736(11)60756-3 - DOI - PMC - PubMed
    1. Goemans NM, Tulinius M, van den Akker JT, Burm BE, Ekhart PF, et al. (2011) Systemic administration of PRO051 in Duchenne’s muscular dystrophy. N Engl J Med 364: 1513–1522. 10.1056/NEJMoa1011367 - DOI - PubMed
    1. Mendell J, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, et al. (2013) Eteplirsen for the treatment of duchenne muscular dystrophy. Ann Neurol. - PubMed

Publication types

Associated data